Download PDF
Aktuelle Rheumatologie 2015; 40(03): 219-222
DOI: 10.1055/s-0035-1548861
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Arthralgien und Arthritiden nach Impfungen: Case Report und Literaturübersicht

Arthralgia and Arthritides following Vaccination: Case Report and Literature Survey
S. Schnarr
1   Klinik für Akutrheumatologie, Rheumaklinik Ostbayern, Bad Füssing
,
C. Göser
1   Klinik für Akutrheumatologie, Rheumaklinik Ostbayern, Bad Füssing
› Author Affiliations
Further Information

Publication History

Publication Date:
28 April 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Autoren beschreiben den Fall einer 17-jährigen Patientin, die im unmittelbaren Anschluss an eine Impfung gegen Humane Papillomaviren (HPV) zunächst eine floride Polyarthritis und im Verlauf eine Mixed Connective Tissue Disease (MCTD, Synonym: Sharp-Syndrom, Mischkollagenose) entwickelte. Die HPV-Typen 16 und 18 gelten als Ursache für etwa 70% aller Zervixkarzinome. Die Ständige Impfkommission (STIKO) empfiehlt in Deutschland seit Sommer 2014 die HPV-Impfung für alle Mädchen im Alter von 9 bis 14 Jahren. Im Anschluss an die Einzelfallbeschreibung gibt der Artikel eine Literaturübersicht zum Auftreten von Arthralgien und Arthritiden nach Impfungen.

Abstract

The authors describe the case of a 17-year-old female patient who developed polyarthritis and mixed connective tissue disease (MCTD, Sharp’s syndrome) subsequently after prophylactic vaccination against human papillomavirus (HPV) infection. HPV types 16 and 18 are considered to cause approximately 70% of all cervical cancers. The German National Vaccination Commission (STIKO) recommends HPV vaccination for all females at the age of 9–14 years. After the case report the article provides a review of the literature about the occurrence of arthralgia and arthritides following vaccination.

Schlüsselwörter

Impfung - Arthritis - Arthralgie - HPV - Mischkollagenose

Key words

vaccination - arthritis - arthralgia - HPV - mixed connective tissue disease
 

  • Literatur

  • 1 Alarcón-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In Kasukawa R, Sharp GC. (eds.) Mixed Connective Tissue Disease and Antinuclear Antibodies. Elsevier; 1987: 33-40
    Google Scholar
  • 2 Hettenkofer HJ, Schneider M, Braun J Hrsg Rheumatologie. 6. Auflage Thieme; 2014: 192
    Google Scholar
  • 3 Zeidler H, Zacher J, Hiepe F Hrsg Interdisziplinäre klinische Rheumatologie. 2. Auflage Springer; 2007: 452
    Google Scholar
  • 4 Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccine and Autoimmune Diseases of the Adult. Discovery Medicin 2010; 9: 90-97
    PubMedGoogle Scholar
  • 5 Mitchell LA, Tingle AJ, MacWilliam L et al. HLA-DR Class II Associations with Rubella Vaccine–Induced Joint Manifestations. J Infect Dis 1998; 177: 5-12
    CrossrefPubMedGoogle Scholar
  • 6 Chantler JK, Ford DK, Tingle AJ. Rubella-Associated Arthritis: Rescue of Rubella Virus from Peripheral Blood Lymphocytes Two Years Postvaccination. Infect Immun 1981; 32: 1274-1280
    PubMedGoogle Scholar
  • 7 Grimaldi-Bensouda L, Guillemot D, Godeau B et al. Autoimmun disorders and qudrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine 2014; 278: 398-408
    PubMedGoogle Scholar
  • 8 Geier DA, Geier MR. A case controll study of serious autoimmun adverse events following hepatitis B immunizitation. Autoimmunity 2005; 35: 295-301
    PubMedGoogle Scholar
  • 9 Soriano A, Verrecchia E, Marinaro A et al. Giant cell arteriitis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus 2012; 21: 153-157
    CrossrefPubMedGoogle Scholar
  • 10 Burbelo PD, Seam N, Groot S. Rapid induction of autoantibodies during ARDS and septic shock. J Transl Med 2010; 14: 97
    PubMedGoogle Scholar
  • 11 McKee AS, Burchill MA, Munks MW et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci USA 2013; 110: E1122-E1131
    CrossrefPubMedGoogle Scholar
  • 12 Didierlaurent AM, Morel S, Lockman L et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. J Immunol 2009; 183: 6186-6197
    CrossrefPubMedGoogle Scholar
  • 13 Shoenfeld Y, Agmon-Levin N. “ASIA” autoimmune/auto inflammatory syndrome induced by adjuvant. J. Autoimmun 2011; 36: 4-8
    CrossrefPubMedGoogle Scholar
  • 14 Tomlijenovic L, Shaw CA. Mecanisms of aluminium adjuvant toxicitiy and autoimmunity in pediatric populations. Lupus 2012; 2: 223-230
    PubMedGoogle Scholar
  • 15 Pellegrino P, Perrone V, Pozzi M et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res 2014; (Epub ahead of print)
    PubMedGoogle Scholar
  • 16 Pelligrino P, Carnovale C, Pozzi M et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmunity Reviews 2014; 13: 736 -741
    CrossrefPubMedGoogle Scholar
  • 17 Gatto M, Agmon-Levin N, Soriano A et al. Human papillomavirus vaccine and systemic lupus eryhematodes. Clinical Rheumatol 2013; 32: 1301-1307
    PubMedGoogle Scholar
  • 18 Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematodes following HPV immunization or infection?. Lupus 2012; 21: 158-161
    CrossrefPubMedGoogle Scholar
  • 19 Slade BA, Leidel L, Vellozzi C et al. Postlicensure saftey surveillance for quadrivalent Human Papillomavirus recombinant vaccine. JAMA 2009; 302: 750-757
    CrossrefPubMedGoogle Scholar
  • 20 Gee J, Naleway A, Shui I et al. Monitoring the safty of quadrivalent human paipillomavirus vaccine. Findings from the Vaccine Safety Datalink Vaccine 2011; 26: 8279-8284
    PubMedGoogle Scholar
  • 21 Stokley S, Jeyaraiah J, Yankey D et al. Human Papilloma virus Vaccination among adolescents, 2007–2013, and Postlincensure Vaccine saftey monitoring 2006–2014; United States. MMWR Morb Mortal Wkly Rep. 2014 63. 620-624
    PubMedGoogle Scholar
  • 22 Druz-Tapias P, Blank M, Anaya JM et al. Infections and vaccines in the etiology of antiphosholipid syndrome. Curr Opin Rheumatol 2012; 24: 389-393
    CrossrefPubMedGoogle Scholar
  • 23 www.rki.de Datenbank der Verdachtsfälle von Impfkomplikationen Paul Ehrlich Institut
    PubMed
  • 24 www.rki.de Nationaler Impfplan, Stand 01.01.2012
    PubMed
  • 25 Verstraeten T, Descamps D, David MP et al. Analysis of adverse events of potential autoimmun aetiology in a large integrated safty database of ASO4 adjuvanted vaccines. Vaccine 2008; 26: 6630-6638
    CrossrefPubMedGoogle Scholar
  • 26 www.rki.de Epid Bull 32/2009
    PubMed
  • 27 Heijstek MW, Scherpenisse M, Groot N et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2014; 73: 1500-1507
    CrossrefPubMedGoogle Scholar
  • 28 Warnatz K, Goldacker S, Gause AM. Impfempfehlungen der Kommission Pharmakotherapie der DGRh. Z Rheumatol 2013; 687 -689
    PubMedGoogle Scholar
  • 29 Müller-Ladner C, Müller-Ladner U. Impfungen bei Patienten mit autoimmunen entzündlichen rheumatischen Erkrankungen. Azrneimitteltherapie 2012; 30: 254-264
    PubMedGoogle Scholar
  • 30 Mok CC, Chan PT, Ho LY. Saftey of quadrivalent human papillomavirus (HPV) vaccine in patients with systematic lupus erythematodes. Ann Rheum Dis 2011; 70: 315
    CrossrefPubMedGoogle Scholar